BioArctic receives new drug substance patent in the US
BioArctic has announced that the US Patent and Trademark Office (USPTO) has granted a new drug substance patent for the antibody ABBV-0805, invented by BioArctic as a potential treatment of Parkinson’s disease. The granted substance patent focuses on the monoclonal antibody ABBV-0805, which selectively binds to and eliminates pathological aggregated forms called oligomers and protofibrils while sparing the physiological monomer form of alpha-synuclein.
Read more...